Hara C, Kamei M, Sakaguchi H, et al. - In the present study, the researchers reported the outcomes of an extension study that assessed the long-term (≧ 48 months) safety and effectiveness associated with the visual acuity (VA), central retinal thickness (CRT), and perfusion status of those 10 eyes treated with intravitreal activated protein C (APC) injections for ischemic central retinal vein occlusion (CRVO). Data reported that the median follow-up was 60 months (range, 48–68 months). There were no complications associated with intravitreal APC, the clinical course improved, and the improved RNP was sustained over time, implying that intravitreal APC may be an alternative treatment for CRVO.